June 13, 2022
Multiple myeloma remains an incurable hematological malignancy despite the availability of numerous treatment options. Resistance to therapy is the primary challenge associated with the disease’…
December 13, 2021
December 6, 2021
August 11, 2021
December 17, 2019
December 12, 2019
MARKET OUTLOOKSuccessive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid…
April 16, 2019
April 8, 2019
March 7, 2019
December 5, 2018
December 26, 2017